Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Molecular Endocrinology (Baltimore, Md.)|September 20, 2008
Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathwaysRamesh Narayanan, Christopher C Coss, Muralimohan Yepuru, et al.
Frontiers in Oncology|April 10, 2025
Potent estrogen receptor β agonists with inhibitory activity <i>in vitro</i>, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cellsLynn M Marcho, Christopher C Coss, Menglin Xu, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
Potent Estrogen Receptor β Agonists with Inhibitory Activity <i>In Vitro</i> , Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer CellsLynn M Marcho, Christopher C Coss, Menglin Xu, et al.
ACS Medicinal Chemistry Letters|April 16, 2025
An Estrogen Receptor β Agonist with AR Antagonist Activity from a Modern Asymmetric <i>De Novo</i> Steroid SynthesisAndrea R Bucknam, Joshua M Nicholson, Hanna S Radomska, et al.
Expert Opinion on Therapeutic Patents|May 16, 2012
Androgen receptor antagonists: a patent review (2008-2011)Michael L Mohler, Christopher C Coss, Charles B Duke, et al.
Cancer Research|November 6, 2019
Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma ProgressionAnees M Dauki, James S Blachly, Esko A Kautto, et al.
International Journal of Molecular Sciences|November 26, 2022
Constitutively Active Androgen Receptor in Hepatocellular CarcinomaEmma J Montgomery, Enming Xing, Moray J Campbell, et al.
Pharmaceutics|April 26, 2025
Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001)Joo Young Na, Min Hai, Kyeongmin Kim, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 7, 2021
Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized DosingSophia Liva, Min Chen, Amir Mortazavi, et al.
Endocrinology|August 16, 2005
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized ratsWenqing Gao, Peter J Reiser, Christopher C Coss, et al.
Pageof 7